Dengue virus has emerged as an important arboviral infection worldwide. As a complex pathogen, with four distinct serotypes, the development of a successful Dengue virus vaccine has proven to be challenging. Here, we describe a novel Dengue vaccine candidate that contains truncated, recombinant, Dengue virus envelope protein from all four Dengue virus serotypes (DEN-80E) formulated with ionizab...

In the United States, two types of vaccines are recommended for the prevention of influenza: an intranasal live attenuated influenza vaccine (LAIV) for eligible individuals aged 2-49 years and unadjuvanted injectable trivalent inactivated vaccines (TIV) for eligible individuals aged ≥ 6 months. Several recent studies have compared the efficacy of the 2 vaccines in children and adults. In childr...

Background: The world is currently confronting the first influenza pandemic of the 21st century. Influenza vaccination is an effective preventive measure, but the unique epidemiological features of swine-origin influenza A (H1N1) (pH1N1) introduce uncertainty as to the best strategy for prioritization of vaccine allocation. We sought to determine optimal prioritization of vaccine distribution a...

This review aims to evaluate the existing literature on Vaccine Supply Chain Management (VSCM). All relevant articles between 2002 and 2022 were systematically collected. The retrieved further analyzed using bibliometric data analysis techniques. unit of is research papers published from 2022. (VSCM) has gained prominence since early 2000 now become voluminous. A first endeavor provide a unifie...

The IAP Committee on Immunization (COI) recommends offering Tdap vaccine instead of Td/ TT vaccine in all children / adolescents who can afford to use the vaccine(1). Tdap is a costly vaccine, which many parents may not be able to afford. There is a need for a less expensive vaccine, though slightly more reactogenic because of whole cell pertussis antigen in reduced quantity, with full dose of ...

BACKGROUND The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccin...

BACKGROUND The world is currently confronting the first influenza pandemic of the 21(st) century. Influenza vaccination is an effective preventive measure, but the unique epidemiological features of swine-origin influenza A (H1N1) (pH1N1) introduce uncertainty as to the best strategy for prioritization of vaccine allocation. We sought to determine optimal prioritization of vaccine distribution ...

Caron L., Brum M.C.S., Moraes M.P., Golde W.T., Arns C.W. & Grubman M.J. 2005. [Granulocyte-macrophage colony-stimulating factor does not increase the potency or efficacy of a foot-and-mouth disease virus subunit vaccine.] Pesquisa Veterinária Brasileira 25(3):150-158. USDA, ARS, PIADC-FMD Research Unit, PO.Box 848, Greenport, NY 11944 0848, USA. E-mail: [email protected] Foot-and-mou...

BACKGROUND Burkholderia pseudomallei is a Category B select agent and the cause of melioidosis. Research funding for vaccine development has largely considered protection within the biothreat context, but the resulting vaccines could be applicable to populations who are at risk of naturally acquired melioidosis. Here, we discuss target populations for vaccination, consider the cost-benefit of d...

BACKGROUND In the light of sub-optimal uptake of the measles, mumps, and rubella (MMR) vaccination, we investigated the factors that influence the intentions of mothers to vaccinate. METHOD A cross-sectional survey of 300 mothers in Birmingham with children approaching a routine MMR vaccination was conducted using a postal questionnaire to measure: intention to vaccinate, psychological variab...